TY - JOUR
T1 - UK vaccination schedule
T2 - Persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
AU - Yates, Tom A.
AU - Paranthaman, Karthikeyan
AU - Yu, Ly Mee
AU - Davis, Elizabeth
AU - Lang, Sarah
AU - Hackett, Scott J.
AU - Welch, Steven B.
AU - Pollard, Andrew J.
AU - Snape, Matthew D.
PY - 2013/6
Y1 - 2013/6
N2 - Objective: To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure. Design: Serological survey. Setting: Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire). Participants: Children from 3 years 4 months to 10 years of age (mean age 6.2 years), vaccinated against HBV from birth following perinatal exposure. Interventions: A single booster dose of the paediatric formulation of a recombinant HBV vaccine. Main outcome measures: Titres of antibody against hepatitis B Surface Antigen (anti-HBs) measured immediately before and 21-35 days after the HBV vaccine booster. Results: Prebooster anti-HBs titres were >10 mIU/ml in 84.6% of children (n=26; 95% CI 65.1 to 95.6%). All children (n=25, 95% CI 86.3 to 100%) had titres >100 mIU/ml after the booster. Conclusions: This study of antibody persistence among UK children born to hepatitis B infected women, immunised with a 3-dose infant schedule with a toddler booster suggests sustained immunity through early childhood. These data should prompt further studies to address the need for a preschool booster. Trial registration: Eudract Number 2008-004785-98.
AB - Objective: To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure. Design: Serological survey. Setting: Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire). Participants: Children from 3 years 4 months to 10 years of age (mean age 6.2 years), vaccinated against HBV from birth following perinatal exposure. Interventions: A single booster dose of the paediatric formulation of a recombinant HBV vaccine. Main outcome measures: Titres of antibody against hepatitis B Surface Antigen (anti-HBs) measured immediately before and 21-35 days after the HBV vaccine booster. Results: Prebooster anti-HBs titres were >10 mIU/ml in 84.6% of children (n=26; 95% CI 65.1 to 95.6%). All children (n=25, 95% CI 86.3 to 100%) had titres >100 mIU/ml after the booster. Conclusions: This study of antibody persistence among UK children born to hepatitis B infected women, immunised with a 3-dose infant schedule with a toddler booster suggests sustained immunity through early childhood. These data should prompt further studies to address the need for a preschool booster. Trial registration: Eudract Number 2008-004785-98.
UR - http://www.scopus.com/inward/record.url?scp=84877609851&partnerID=8YFLogxK
U2 - 10.1136/archdischild-2012-302153
DO - 10.1136/archdischild-2012-302153
M3 - Article
C2 - 23476003
AN - SCOPUS:84877609851
SN - 0003-9888
VL - 98
SP - 429
EP - 433
JO - Archives of Disease in Childhood
JF - Archives of Disease in Childhood
IS - 6
ER -
